Vifor pharma and travere therapeutics announce licensing agreement for the commercialization of sparsentan in europe, australia and new zealand

St. gallen, switzerland & san diego, calif.--(business wire)--regulatory news: ad hoc announcement pursuant to art. 53 lr vifor pharma group and travere therapeutics, inc. (nasdaq: tvtx) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in europe, australia and new zealand. sparsentan is a novel investigational product candidate currently being evaluated in pivotal phase-iii clinical studies for the treatment of
TVTX Ratings Summary
TVTX Quant Ranking